The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $45.46

Today's change+0.53 +1.18%
Updated November 28 1:02 PM EST. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $45.46

Today's change+0.53 +1.18%
Updated November 28 1:02 PM EST. Delayed by at least 15 minutes.

Novo Nordisk A/S Hits New 20-day High

Novo Nordisk A/S closed up Friday by (U.S.)$0.53 or 1.18% to (U.S.)$45.46 and setting a new 20-day high. Over the last five days, shares have gained 2.64% and 23.02% year to date. Shares have outperformed the S&P 500 by 17.83% during the last year.

Key company metrics

  • Open(U.S.) $45.60
  • Previous close(U.S.) $44.93
  • High(U.S.) $45.87
  • Low(U.S.) $45.38
  • Bid / Ask(U.S.) $43.65 / (U.S.) $46.00
  • YTD % change+23.02%
  • Volume428,447
  • Average volume (10-day)1,001,540
  • Average volume (1-month)1,759,013
  • Average volume (3-month)1,488,602
  • 52-week range(U.S.) $34.81 to (U.S.) $49.11
  • Beta0.93
  • Trailing P/E27.82×
  • P/E 1 year forward26.00×
  • Forward PEG2.06×
  • Indicated annual dividend(U.S.) $0.83
  • Dividend yield1.83%
  • Trailing EPS(U.S.) $1.63
Updated November 28 1:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+30.79%

Based on its net profit margin of 30.79%, Novo Nordisk A/S is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.93%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2014Q1/2014Q4/2013Q3/2013
Fiscal Quarter Endvalues in $ millions unless otherwise notedJun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013Sep 30, 201309/30/2013
Revenue21,62920,34321,69820,511
Total other revenue--------
Total revenue21,62920,34321,69820,511
Gross profit17,95816,87718,29816,986
Total cost of revenue3,6713,4663,4003,525
Total operating expense12,89612,31014,34412,519
Selling / general / administrative6,3545,8917,5576,351
Research & development3,0753,1683,5662,795
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total-204-215-179-152
Operating income8,7338,0337,3547,992
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax8,9898,3017,7908,299
Income after tax6,9946,4586,0536,415
Income tax, total1,9951,8431,7371,884
Net income6,9946,4586,0536,415
Total adjustments to net income--------
Net income before extra. items6,9946,4586,0536,415
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items6,9946,4586,0536,415
Inc. avail. to common incl. extra. items6,9946,4586,0536,415
Diluted net income6,9946,4586,0536,415
Dilution adjustment0------
Diluted weighted average shares2,6372,6532,6662,682
Diluted EPS excluding extraordinary itemsvalue per share2.652.432.272.39
Dividends per sharevalue per share0.000.003.350.00
Diluted normalized EPSvalue per share2.652.432.272.39